Edition:
United Kingdom

Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

13.84CAD
23 May 2018
Change (% chg)

$0.34 (+2.52%)
Prev Close
$13.50
Open
$13.44
Day's High
$14.06
Day's Low
$13.00
Volume
332,141
Avg. Vol
175,709
52-wk High
$14.33
52-wk Low
$4.96

Chart for

About

Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs to promote healthy living for human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of... (more)

Overall

Beta: 1.84
Market Cap(Mil.): $588.89
Shares Outstanding(Mil.): 74.92
Dividend: --
Yield (%): --

Financials

  TH.TO Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -0.19 -- --
ROI: -32.89 14.84 14.38
ROE: -39.35 16.34 16.07

BRIEF-FDA Releases Theratechnologies From Post-Approval Commitments Related To EGRIFTA

* FDA RELEASES THERATECHNOLOGIES FROM POST-APPROVAL COMMITMENTS RELATED TO EGRIFTA® (TESAMORELIN FOR INJECTION)

01 May 2018

BRIEF-Theratechnologies To Seek Regulatory Approval Of Trogarzo In Europe

* THERATECHNOLOGIES TO SEEK REGULATORY APPROVAL OF TROGARZO™ (IBALIZUMAB) IN EUROPE

24 Apr 2018

BRIEF-Theratechnologies Reports Q1 Loss Per Share C$0.04

* THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER OF 2018

05 Apr 2018

BRIEF-Theratechnologies Announces FDA Approval Of Trogarzo (Ibalizumab-Uiyk) Injection

* THERATECHNOLOGIES ANNOUNCES FDA APPROVAL OF BREAKTHROUGH THERAPY, TROGARZO™ (IBALIZUMAB-UIYK) INJECTION, THE FIRST HIV-1 INHIBITOR AND LONG-ACTING MONOCLONAL ANTIBODY FOR MULTIDRUG RESISTANT HIV-1 Source text for Eikon: Further company coverage:

06 Mar 2018

BRIEF-Theratechnologies Reports Q4 Loss Per Share Of C$0.06

* THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2017

07 Feb 2018

Earnings vs. Estimates